AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
167.76
+1.19 (0.71%)
At close: Nov 20, 2024, 4:00 PM
167.68
-0.08 (-0.05%)
After-hours: Nov 20, 2024, 7:52 PM EST
AbbVie Employees
AbbVie had 50,000 employees as of January 31, 2024. The number of employees did not change compared to the previous year.
Employees
50,000
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$1,110,660
Profits / Employee
$101,620
Market Cap
296.46B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Jan 31, 2024 | 50,000 | 0 | - |
Jan 31, 2023 | 50,000 | 0 | - |
Jan 31, 2022 | 50,000 | 3,000 | 6.38% |
Jan 31, 2021 | 47,000 | 17,000 | 56.67% |
Jan 31, 2020 | 30,000 | 0 | - |
Jan 31, 2019 | 30,000 | 1,000 | 3.45% |
Jan 31, 2018 | 29,000 | -1,000 | -3.33% |
Jan 31, 2017 | 30,000 | 2,000 | 7.14% |
Jan 31, 2016 | 28,000 | 2,000 | 7.69% |
Jan 31, 2015 | 26,000 | 1,000 | 4.00% |
Jan 31, 2014 | 25,000 | 3,500 | 16.28% |
Jan 31, 2013 | 21,500 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
ABBV News
- 22 hours ago - My Dividend Stock Portfolio: New October Dividend Record - 100 Holdings With 15 Buys - Seeking Alpha
- 1 day ago - Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer's Transgenic Mice - Business Wire
- 2 days ago - High-Conviction Investing - 4 Of The Best Dividend Stocks Money Can Buy - Seeking Alpha
- 3 days ago - AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer - PRNewsWire
- 6 days ago - AbbVie Awards 20 Individuals Living With Migraine To Support Career Aspirations - PRNewsWire
- 7 days ago - Aldeyra's FDA Resubmission And AbbVie Option Revitalize Reproxalap's Prospects - Seeking Alpha
- 8 days ago - AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio - Benzinga
- 8 days ago - AbbVie's disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say - Market Watch